Symptoms Experienced and Quality of Life in Patients With Breast Cancer Receiving Radiotherapy Across One Year

Symptoms Experienced and Quality of Life in Breast Cancer Receiving Radiotherapy

Sponsors

Lead sponsor: Chulabhorn Cancer Center

Source Chulabhorn Cancer Center
Brief Summary

EORTC-QLQ-30 questionnaire filled in by participants 6 times

Detailed Description

EORTC-QLQ-30 questionnaire filled in by participants 6 times

- 1st before receive radiotherapy

- 2nd after receive radiotherapy

- 3th 1 month after receive radiotherapy

- 4th 3 month after receive radiotherapy

- 5th 6 month after receive radiotherapy

- 6th 1 year after receive radiotherapy

Overall Status Completed
Start Date March 1, 2015
Completion Date February 28, 2017
Primary Completion Date February 28, 2017
Study Type Observational [Patient Registry]
Primary Outcome
Measure Time Frame
symptoms experienced Change from Baseline symptoms experienced at 1 month,3 month,6 month,1 year after radiotherapy
Secondary Outcome
Measure Time Frame
quality of life Change from Baseline quality of life at 1 month,3 month,6 month,1 year after radiotherapy
Enrollment 103
Condition
Intervention

Intervention type: Other

Intervention name: Questionnaire

Description: The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.

Arm group label: questionnaire

Other name: EORTC-QLQ-30 Questionnaire

Eligibility

Sampling method: Probability Sample

Criteria:

Inclusion Criteria:

- good consciousness

- ability to understand and provide information

- no hearing impairment

- Eastern Cooperative Oncology Group performance level of 0 to 2

Exclusion Criteria:

- prior radiotherapy

Gender: Female

Minimum age: 20 Years

Maximum age: 80 Years

Healthy volunteers: No

Overall Official
Last Name Role Affiliation
Saengrawee Thanthong, M.N.S Principal Investigator Chulabhorn Hospital
Verification Date

April 2017

Responsible Party

Responsible party type: Principal Investigator

Investigator affiliation: Chulabhorn Cancer Center

Investigator full name: Saengrawee Thanthong

Investigator title: Principal Investigator

Has Expanded Access No
Arm Group

Arm group label: questionnaire

Description: EORTC-QLQ-30 questionnaire

Patient Data Yes
Study Design Info

Observational model: Case-Control

Time perspective: Prospective

Source: ClinicalTrials.gov